Annovis Bio, Inc. has announced a registered direct offering on October 10, 2025, for 3,150,000 shares at $1.50 each, expecting to raise approximately $6.0 million for Alzheimer's clinical development and corporate purposes. This event is significant and has a positive sentiment among investors.